Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020

Business Wire April 8, 2020

Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

Business Wire March 25, 2020

Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

Business Wire March 2, 2020

Exelixis Announces Webcasts of Investor Conference Presentations in March

Business Wire February 26, 2020

Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

Business Wire February 25, 2020

Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Business Wire February 25, 2020

Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020

Business Wire February 12, 2020

Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Business Wire February 10, 2020

Exelixis Announces Webcasts of Investor Conference Presentations in February

Business Wire February 6, 2020

Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma

Business Wire January 29, 2020

Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma

Business Wire January 24, 2020

Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

Business Wire January 12, 2020

Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

Business Wire January 7, 2020

Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Business Wire January 7, 2020

Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

Business Wire December 19, 2019

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

Business Wire December 13, 2019

Exelixis Announces Webcasts of Investor Conference Presentations in December

Business Wire November 26, 2019

Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

Business Wire November 12, 2019

Exelixis' Partner Ipsen Announces Health Canada's Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

Business Wire November 12, 2019

Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

Business Wire November 7, 2019